Sex differences in the pharmacokinetics of anticancer drugs: a systematic review

This publication has 170 references indexed in Scilit:

• Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors
  Cancer, 2022
• Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
  Clinical Pharmacology & Therapeutics, 2020
• Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials
  JAMA Network Open, 2020
• Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
  Molecular Oncology, 2020
• Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
  JAMA Oncology, 2019
• Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor
  JAMA Oncology, 2018
• Association of Patient Sex With Chemotherapy-Related Toxic Effects
  JAMA Oncology, 2018
• Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
  Clinical Pharmacology & Therapeutics, 2017
• Rational use of medicines in older adults: Can we do better during clinical development?
  Clinical Pharmacology & Therapeutics, 2015
• Differences in toxicity between men and women treated with 5‐fluorouracil therapy for colorectal carcinoma
  Cancer, 2005